Anaplastic large-cell lymphoma (ALCL) makes up approximately 15% of pediatric non-Hodgkin's lymphoma (NHL) and the vast majority of them is associated with the t(2;5) translocation that results in the expression of a hybrid oncogenic tyrosine kinase. It consists of the amino terminus of the nuclear protein nucleophosmin (NPM) fused to the intracytoplasmic region of the anaplastic lymphoma kinase (ALK) that impacts many cellular responses including proliferation, growth and apoptosis. 1 In addition to its direct effects of ALK on signal transduction pathways, ALK overexpression may also induce a host immune reaction, giving rise to autologous anti-ALK antibodies in patients with ALK-positive ALCL. Circulating antibodies against NPM-ALK were originally reported in 11 ALK-positive ALCL patients using an immunocytochemical approach. 2 In that study, no conclusions concerning the clinical significance of anti-NPM-ALK antibodies could be drawn, due to the small number of patients; however, a tendency to higher antibody levels in pretreatment blood samples was observed.
Recently, we demonstrated that minimal bone marrow (BM) involvement at diagnosis is a common event in pediatric ALCL and that minimal BM disease monitoring can identify patients at risk of relapse. 3 In addition, Damm-Welk et al. 4 showed that patients with more than 10 normalized copy numbers (NCNs) NPM-ALK in BM had a cumulative incidence of relapse (CI-R) of 71±14% compared with CI-R of 18±6% for patients with 10 or fewer NCNs (Po0.001) and that quantitative PCR for NPM-ALK in BM and peripheral blood (PB) is highly concordant.
In this study, we assessed the levels of anti-NPM-ALK antibodies at diagnosis and at stop therapy in plasma of children with ALCL treated according to the ALCL-99 protocol 5 and evaluated the possible correlation with minimal residual disease (MRD) status during chemotherapy.
Cytocentrifuge preparations of COS-1 cells, transiently transfected with a plasmid cDNA encoding for NPM-ALK, or with empty vector, were prepared and stained using patient's plasma in an indirect immunoperoxidase technique as previously described. 2 The cytocentrifuge preparations were incubated with patient's plasma diluted from 1:50 to 1:60 750. The cutoff for a positive result was taken as the highest dilution before the labeling of the NPM-ALK transfectants disappeared. The MRD study in PB was conducted using a TaqMan-based quantitative real-time PCR (RQ-PCR) for NPM-ALK developed according to the standardized protocol of the Europe Against Cancer (EAC) program for TaqMan-based RQ-PCR. 6 ABL was selected as the control gene to compensate for variations in RNA integrity and differences in the PCR step. The NPM-ALK fusion transcript copy number was normalized to the copy numbers of the ABL gene. The absolute copy numbers of NPM-ALK and ABL were estimated with their corresponding standard curves. The NCNs were expressed as copy number of the NPM-ALK per 10 4 copies ABL. 4 A total of 28 children affected by de novo ALCL (median age 9.9 years; median follow-up 3 years) were enrolled in this study between September 2001 and June 2007. The study was approved by the local ethics committees and informed consent was obtained for all of the patients. Clinical characteristics of the patients are shown in Table 1 . Histological and immunohistochemical diagnosis were centrally reviewed. All cases were CD30 and ALK-positive and were negative for B-cell markers CD20 and CD79a. Of the 28 ALCL patients studied, seven suffered a relapse and one a disease progression.
Circulating antibodies recognizing the NPM-ALK protein kinase were detected at diagnosis in 25 out of 28 samples (Figure 1a ). Of note, only 4 of 23 high-risk (HR) patients showed the higher tested titer (1/60 650), whereas this was observed in 3 of 5 standard-risk (SR) patients.
To define the cutoff value that may predict relapse with the highest sensitivity and specificity, a receiver-operator characteristic curve (ROC) was calculated. The sensitivity of the assay for each antibody titer group was defined based on the percentage of relapse in each group and specificity was calculated using the percentage of non-relapse in all groups but the test one. We Table 1 Characteristics of the patient population St.Jude's staging system.
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found that the antibody titer cutoff value of 1 of 2250 had the best sensitivity and specificity (sensitivity 75%, specificity 55%) compared with other cutoff values. Patients with antibody titer below cutoff had a trend to higher relapse rate (40%) than children with higher antibody titers (15%), although not statistically significant (P ¼ 0.2). PB samples were positive for NPM-ALK transcript in 15 (54%) of the 28 patients at diagnosis, whereas only one was positive at morphologic analysis (Figure 1b) . In five of the eight patients who suffered a relapse or disease progression (one patient) and in 8 of 20 that remained in first complete remission, more than 10 NCNs NPM-ALK were detected in PB at diagnosis. Although in our relatively small cohort of patients it did not reach statistical significance, the relationship between MRD and event is in line with the results of Damm-Welk et al. who reported that patients with more than 10 NCNs NPM-ALK in BM and/or PB have a significantly worse prognosis. 4 Subsequently, we examined whether the level of minimal disseminated disease (MDD) in PB and the level of antibody titer could identify, with higher sensitivity, a group of patients at greater risk of relapse. Interestingly, we found that MDD positivity with more than 10 NCNs NPM-ALK in PB and antibody titer p1/2250 was significantly associated in univariate analysis with the risk of relapse, as 62.5% of patients with these two characteristics relapsed compared with only 15% of the remaining patients (Fisher's exact test, P ¼ 0.02) (Figure 2) .
We also studied MRD and antibody titer at the end of therapy: MRD became negative for all patients except two (Figure 1b) , whereas the antibody titer had an intriguing pattern (Figure 1a ). When focusing on relapsed patients (Figure 3a) , we found that in all of them, except one, the NPM-ALK antibody titer decreased below 1 of 100 at stop therapy and that at relapse there was a rebound that, however, never reached the levels observed at diagnosis.
Conversely, most of the patients who did not relapse (14/20), maintained a high antibody titer in a higher percentage of cases, compared with the first group (Figure 3b ). Of note, in four of those patients the titer remained unchanged (in three very high level) for the entire duration of treatment.
Our data confirm the high prevalence of anti-ALK antibodies in pediatric ALK-positive ALCL. They also suggest a relationship between MRD and anti-ALK antibody response that may contribute to a better identification of patients with poor prognosis. The titer and kinetics of anti-ALK antibody may also Letters to the Editor represent prognostic markers in ALCL, but they need further investigation in the context of a larger series of patients and in conjunction with additional immunological parameters. The increasing amount of knowledge on several immunological aspects of ALCL yielded recently, including evidence of in vivo anti-ALCL immune reactivity, 7, 8 warrants the design of vaccination trials to be tested in ALCL patients.
